

Elena Castro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4163312/publications.pdf>

Version: 2024-02-01

65
papers

4,620
citations

172457

29
h-index

114465

63
g-index

66
all docs

66
docs citations

66
times ranked

6308
citing authors

#	ARTICLE	IF	CITATIONS
1	Germline <i>BRCA</i> Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1748-1757.	1.6	641
2	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. <i>British Journal of Cancer</i> , 2011, 105, 1230-1234.	6.4	320
3	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. <i>European Urology</i> , 2015, 68, 186-193.	1.9	279
4	PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 490-503.	1.6	255
5	Germline BRCA1 mutations increase prostate cancer risk. <i>British Journal of Cancer</i> , 2012, 106, 1697-1701.	6.4	251
6	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
7	The genetic epidemiology of prostate cancer and its clinical implications. <i>Nature Reviews Urology</i> , 2014, 11, 18-31.	3.8	207
8	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	1.9	195
9	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , 2017, 71, 417-425.	1.9	169
10	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	10.7	159
11	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	1.9	148
12	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	27.8	142
13	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology</i> , The, 2012, 13, 1114-1124.	10.7	125
14	The role of BRCA1 and BRCA2 in prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 409-414.	1.6	124
15	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	3.5	105
16	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	10.7	97
17	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. <i>Human Genetics</i> , 2011, 129, 687-694.	3.8	83
18	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. <i>European Urology</i> , 2018, 74, 562-572.	1.9	80

#	ARTICLE	IF	CITATIONS
19	BRCA2 and Other DDR Genes in Prostate Cancer. <i>Cancers</i> , 2019, 11, 352.	3.7	72
20	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	5.9	70
21	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
22	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	6.4	63
23	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	1.3	58
24	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2019, 11, 1355.	3.7	54
25	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	10.7	48
26	Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. <i>European Journal of Cancer</i> , 2021, 147, 74-83.	2.8	42
27	High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. <i>Annals of Oncology</i> , 2015, 26, 2293-2300.	1.2	36
28	Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (<scp>SNP</scp>) profiles in an active surveillance cohort. <i>BJU International</i> , 2013, 112, 666-673.	2.5	34
29	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747.	2.9	32
30	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , 2021, 79, 519-529.	1.9	30
31	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 06784314 rge /Ove	2.8	29
32	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
33	Inherited mutations in DNA repair genes and cancer risk. <i>Current Problems in Cancer</i> , 2017, 41, 251-264.	2.0	28
34	Targeting DNA Repair. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 353-356.	2.0	27
35	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016, 21, 716-722.	3.7	27
36	Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. <i>Scientific Reports</i> , 2013, 3, 2059.	3.3	26

#	ARTICLE	IF	CITATIONS
37	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. <i>Psycho-Oncology</i> , 2015, 24, 1492-1499.	2.3	23
38	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	3.7	22
39	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 2855.	3.7	16
40	Men's all very well reading the letters in the genome, but it's a long way to being able to write Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. <i>Familial Cancer</i> , 2014, 13, 625-635.	1.9	15
41	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	3.7	15
42	Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. <i>Psycho-Oncology</i> , 2017, 26, 1987-1993.	2.3	12
43	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	6.4	12
44	Prostate Cancer Screening in BRCA and Lynch Syndrome Mutation Carriers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e50-e55.	3.8	12
45	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , 2021, 81, 1382-1389.	2.3	10
46	Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 763-766.	1.9	9
47	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , 2021, 13, 2334.	3.7	9
48	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. <i>Cancers</i> , 2022, 14, 2950.	3.7	9
49	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e19-202.e28.	1.6	8
50	Prostate Cancer Screening in BRCA and Lynch Syndrome Mutation Carriers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e50-e55.	3.8	7
51	Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. <i>European Journal of Radiology Open</i> , 2014, 1, 22-27.	1.6	6
52	Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients. <i>Clinical and Translational Oncology</i> , 2014, 16, 158-165.	2.4	6
53	Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients. <i>European Urology Oncology</i> , 2021, 4, 315-318.	5.4	6
54	Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects. <i>European Journal of Cancer</i> , 2021, 159, 87-97.	2.8	6

#	ARTICLE	IF	CITATIONS
55	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	2.8	4
56	Third Nerve Palsy as the Initial Presenting Sign of Metastatic Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 407-408.	1.3	3
57	Re: Germline BRCA Mutations are Associated with Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 2093-2094.	0.4	3
58	Neutrophil to lymphocyte ratio: another drop in the ocean of CRPC biomakers?. <i>Annals of Oncology</i> , 2015, 26, 622-623.	1.2	3
59	DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review. <i>Future Oncology</i> , 2021, 17, 853-864.	2.4	3
60	Comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 164-164.	1.6	2
61	Implications of DNA damage repair alterations for the management of prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 302-310.	1.8	1
62	TP53: Another Piece of the Prostate Cancer Genetics Puzzle. <i>European Urology</i> , 2022, 81, 251-252.	1.9	1
63	The risk of taking the part by the whole. <i>Annals of Oncology</i> , 2008, 19, 1975-1976.	1.2	0
64	Importancia del radio-223 en la pr�ctica hospitalaria. Visi�n del onc�logo m�dico. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2019, 38, 106-111.	0.0	0
65	B2B: Prostate Cancer. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, S30-S50.	0.4	0